Related Experiment Video
Updated: Jan 29, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Update on emerging biomarkers in lung cancer
Eric H Bernicker1, Timothy Craig Allen2, Phillip T Cagle3
1Houston Methodist Hospital, Cancer Center, Houston, Texas, USA.
Abstract:
There has been considerable progress made in identifying oncogenic driver mutations in advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make treatment decisions. These mutations are clinically important as available targeted therapies can achieve significant responses and prolonged disease control. This review will summarize the current guidelines for biomarker testing and available therapeutic agents.
More Related Videos
Related Concept Videos
Emerging Adulthood
Lung Capacity
Introduction Cardiac Emergencies
Applications of GIS: Disaster Management and Emergency Response
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Pleura of the Lungs

